Investigation of in vitro activity of colistin and tygecyclin against Stenotrophomonas maltophilia isolates

Yeliz TANRIVERDİ ÇAYCI; İlknur BIYIK; Gonca YILMAZ; Kemal BİLGİN; Asuman BIRINCI

Makale detayları

Investigation of in vitro activity of colistin and tygecyclin against Stenotrophomonas maltophilia isolates

Yazarlar:

Yeliz TANRIVERDİ ÇAYCI | İlknur BIYIK | Gonca YILMAZ | Kemal BİLGİN | Asuman BIRINCI

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Experimental and Clinical Medicine 2021 Vol.38 Issue 4, pp.529-532

Belge Tipi:

Makale

Yayın Tarihi:

10/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000507265

Sıklık:

Üç Aylık

eISSN:

1309-5129

pISSN:

1309-4483

Özet:

 

Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen, causing infections whose management is often problematic due to its inherent resistance to many antibiotics. In this study, we aimed to investigate the antimicrobial susceptiblity of colistin and tygecyclin as an alternative treatment options for S. maltophilia infections. A total of 122 S. maltophilia isolates were tested. Minimum inhibitory concentration (MIC) values of colistin and tygecycline were determined by broth microdilution method. Susceptibility of TMP/SMX and levofloxacin (LVX) were determined by disc diffusion method and MIC value of ceftazidime (CAZ) was determined by using E-test. Out of 122 S. maltophilia isolates, 5 (4%) of them were resistant to TMP-SXM. MIC range was 0.125- >512 μg/ml and MIC50 64 μg/ml, MIC90 512 μg/ml for colistin. MIC range for tygecyclin was detected as 0.5- >8, MIC50 2 μg/ml and MIC90 8 μg/ml. Tygecyclin resistance was detected as 66.4% according to the EUCAST guideline and 13.1% according to the USA-FDA breakpoints. And colistin resistance was determined as 86.9% according to  both guidelines.

Makale detayları

Investigation of in vitro activity of colistin and tygecyclin against Stenotrophomonas maltophilia isolates

Yazarlar: Yeliz TANRIVERDİ ÇAYCI | İlknur BIYIK | Gonca YILMAZ | Kemal BİLGİN | Asuman BIRINCI

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Sağlık teşvikleri

Dergi: Journal of Experimental and Clinical Medicine 2021 Vol.38 Issue 4, pp.529-532

Belge Tipi: Makale

Yayın Tarihi: 10/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000507265

Sıklık: Üç Aylık

eISSN: 1309-5129

pISSN: 1309-4483

Sayı

Yazarlar:

Yeliz TANRIVERDİ ÇAYCI | İlknur BIYIK | Gonca YILMAZ | Kemal BİLGİN | Asuman BIRINCI

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Experimental and Clinical Medicine 2021 Vol.38 Issue 4, pp.529-532

Belge Tipi:

Makale

Yayın Tarihi:

10/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000507265

Sıklık:

Üç Aylık

eISSN:

1309-5129

pISSN:

1309-4483